Top Casino Stocks To Watch For 2019

Related LVS 5 Trends U.S. Casino Investors Need To Watch Deutsche Bank Says Buy MGM Following SotP Analysis, 'Encouraging' Q4 Metrics Macau at the crossroads (Seeking Alpha)
Related Benzinga's Top Upgrades Morgan Stanley Revises Triple-Net REIT Ratings Prior To Q2 Earnings

One of the more unique technical analysis metrics used to determine buy and sell signals is Parabolic SAR. Developed by Welles Wilder in 1978, the “SAR” stands for “stop and reverse.”

Top Casino Stocks To Watch For 2019: Globus Medical, Inc.(GMED)

Advisors’ Opinion:

  • [By Logan Wallace]

    Globus Medical Inc (NYSE:GMED) – Research analysts at William Blair cut their Q2 2018 earnings per share (EPS) estimates for shares of Globus Medical in a report released on Thursday, May 3rd. William Blair analyst K. Krum now forecasts that the medical device company will earn $0.35 per share for the quarter, down from their previous estimate of $0.37. William Blair also issued estimates for Globus Medical’s Q3 2018 earnings at $0.35 EPS, FY2018 earnings at $1.52 EPS, Q1 2019 earnings at $0.42 EPS, Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.46 EPS and FY2019 earnings at $1.71 EPS.

  • [By Joseph Griffin]

    Schwab Charles Investment Management Inc. raised its stake in shares of Globus Medical Inc (NYSE:GMED) by 8.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 421,775 shares of the medical device company’s stock after purchasing an additional 31,253 shares during the period. Schwab Charles Investment Management Inc. owned 0.44% of Globus Medical worth $21,013,000 at the end of the most recent reporting period.

Top Casino Stocks To Watch For 2019: New York REIT, Inc.(NYRT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Media coverage about New York REIT (NYSE:NYRT) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. New York REIT earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the real estate investment trust an impact score of 46.2668688678986 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Joseph Griffin]

    Media headlines about New York REIT (NYSE:NYRT) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. New York REIT earned a news impact score of 0.17 on Accern’s scale. Accern also gave news coverage about the real estate investment trust an impact score of 46.6379734958041 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Max Byerly]

    New York REIT (NYSE:NYRT) reached a new 52-week high and low on Monday . The stock traded as low as $17.51 and last traded at $17.60, with a volume of 7341 shares traded. The stock had previously closed at $17.85.

Top Casino Stocks To Watch For 2019: Aurora Cannabis Inc. (ACBFF)

Advisors’ Opinion:

  • [By Sean Williams]

    Perhaps no company will be guiltier of drowning its investors in share dilution more than Aurora Cannabis (NASDAQOTH:ACBFF). After finishing fiscal 2014 with just over 16 million shares outstanding, Aurora Cannabis ended the third quarter of fiscal 2018 with almost 565 million shares outstanding. Having recently announced an all-share acquisition of MedReleaffor what amounted to $2.5 billion at the time, Aurora Cannabis could have in excess of 1 billion shares outstanding by this time next year. Aurora would have to earn CA$100 million ($77 million) just to generate $0.10 in annual EPS. That’s insane, and it’s all the more reason to avoid it and a handful of dilution-happy pot stocks.

  • [By Sean Williams]

    For example, Aurora Cannabis (NASDAQOTH:ACBFF) has suggested that it could lead the pack by producing 570,000 kilograms of cannabis-equivalent production yearly, when at full capacity. But when Oct. 17 rolls around, it’s not going to be anywhere near this level. Its 800,000-square-foot Aurora Sky facility will be done by then, and it’s capable of just over 100,000 kilograms of cannabis production annually, but its recently announced Aurora Sun facility in Alberta, and its partnered Aurora Nordic project, won’t be completely online until a later date.

  • [By ]

    What are the risks? First off, the Cannabis market in Canada is already competitive, and it’s the fifth largest company behind the likes of Canopy (OTCPK:TWMJF), Aurora (OTCQX:ACBFF), Aphria (OTCQB:APHQF), Medreleaf (OTCPK:MEDFF), and Cronos (OTC:CRON). What’s more, there are approximately 228 million fully diluted shares, selling at $3.16/share ($4.04/share $CAD), and the company generated $CAD4.09mm in 2017 revenues. That’s quite a premium, and Hydropothecary Corp. trades expensively at a 225x sales multiple. Caveat emptor.

  • [By Sean Williams]

    Over the past year and change, three cannabis growers have maintained their position near the head of the pack in terms of production: Aurora Cannabis (NASDAQOTH:ACBFF), Canopy Growth Corporation, and Aphria. According to company estimates, Aurora Cannabis and Aphria are on track to produce 570,000 kilograms (assuming the completed purchase of MedReleaf (NASDAQOTH:MEDFF)) and 255,000 kilograms of cannabis annually, respectively, with Canopy Growth likely producing around 500,000 kilograms a year, by my best estimate.

  • [By Keith Speights]

    Big Canadian marijuana growers like Canopy Growth (NYSE:CGC), Aurora Cannabis (NASDAQOTH:ACBFF), and Aphria (NASDAQOTH:APHQF) aren’t building a baseball field in hopes that famous dead players will show up. However, they are cranking up production capacity in the hopes that there’ll be a huge demand for recreational marijuana in Canada.

  • [By ]

    As of the time of this writing, the average price to sales ratio of the large Canadian cannabis producers is 40 (Aurora (OTCQX:ACBFF): 33; Canopy (OTCPK:TWMJF): 65; Aphria (OTCQB:APHQF): 28.5; MedReleaf (OTCPK:MEDFF): 35). Given iAnthus’ vertical integration and lack of competition, their margins should be significantly better than any of those firms. However, since they operate in the US where there is greater legal risk, we will reduce that multiple by half. Assuming the low end of expected revenue for 2018 of $20 million, and a P/S of 20, we arrive at a valuation of $400,000,000, giving us a one year price target of $5/share.

Leave a Reply

Your email address will not be published. Required fields are marked *